Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Krystal Scarbrough

Nurse Practitioner, Gerontology Warrensburg, MO Nurse Practitioner

NPI 1326654443 CMS profile 10562004

407 E Russell Ave Bldg C, Warrensburg, MO 64093

Open in the dashboard

General payments

$1,947

90 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krystal Scarbrough of Warrensburg, MO is reported in the CMS Open Payments database as having received $1,947 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $323 16
2024 General $199 10
2023 General $444 17
2022 General $579 29
2021 General $402 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krystal Scarbrough
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Krystal Scarbrough were reported at $323. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Krystal Scarbrough Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $402 $133 $44–$396 $132
2022 $579 $142 $48–$452 $149
2023 $444 $158 $53–$482 $160
2024 $199 $171 $55–$533 $164
2025 $323 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $613 28 payments
  2. Novo Nordisk Inc $448 20 payments
  3. Lilly USA, LLC $169 6 payments
  4. Dexcom, Inc. $141 6 payments
  5. Rhythm Pharmaceuticals, Inc. $120 1 payment
  6. Amgen Inc. $60 4 payments
  7. Novartis Pharmaceuticals Corporation $52 3 payments
  8. Otsuka America Pharmaceutical, Inc. $47 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $42 3 payments
  10. AstraZeneca Pharmaceuticals LP $38 2 payments
  11. Other $218 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,935 89 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $323 15 payments
  2. Wegovy $281 4 payments
  3. UBRELVY $174 8 payments
  4. LO LOESTRIN FE $152 6 payments
  5. Dexcom G6 Transmitter $141 6 payments
  6. VRAYLAR $138 7 payments
  7. Ozempic $136 14 payments
  8. RYBELSUS $135 14 payments
  9. Imcivree $120 1 payment
  10. Saxenda $118 1 payment
  11. Other $936 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

2,006

Median for Nurse Practitioner: 389

Drug cost

$148,196

Median for Nurse Practitioner: $21,885

Branded share of claims

21.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 48 $48,775
Mounjaro Tirzepatide Brand 30 $45,857
Eliquis Apixaban Brand 20 $19,099
Rybelsus Semaglutide Brand 11 $12,229
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 12 $2,622
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $2,473
Albuterol Sulfate Hfa Albuterol Sulfate Brand 81 $1,619
Gabapentin Generic 59 $1,262
Omeprazole Generic 79 $1,240
Pantoprazole Sodium Generic 101 $828

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $38
$38 — —
QULIPTA
  • AbbVie, Inc. $38
$38 — —
RYBELSUS
  • Novo Nordisk Inc $25
$25 11 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $17
$17 — —
Wegovy
  • Novo Nordisk Inc $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record